CATALYST FINANCIAL PARTNERS LLC

Position in GILD — Gilead Sciences, Inc.

CIK 1927537 BOSTON, MA

Position in GILD

as of Jun 30, 2026 · filed Jul 30, 2026 Compact

Position Value

$722,159

-$40,891 QoQ

Shares Held

5,716

+4.4% QoQ

Ownership

0.000%

of shares outstanding

% of Portfolio

0.14%

of 13F equity value

Holder Rank

#1,218

of 2,266 holders

Holding Since

Dec 2022

15 quarters on record

Voting authority Sole 0% Shared 0% None 100%

Healthcare · as of Jun 30, 2026

CATALYST FINANCIAL PARTNERS LLC holds $23,806,391 across 9 Drug Manufacturers - General names. GILD ranks #6 (3.0% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	LLY	ELI LILLY & Co	6,449	$7,735,124
2	JNJ	Johnson & Johnson	24,867	$6,315,471
3	ABBV	AbbVie Inc.	15,393	$3,873,494
4	MRK	Merck & Co., Inc.	20,205	$2,596,342
5	AMGN	Amgen Inc	3,386	$1,226,138
6	GILD	Gilead Sciences, Inc. This page	5,716	$722,159
7	PFE	Pfizer Inc	25,150	$605,612
8	BMY	Bristol Myers Squibb Co	8,894	$512,472

15 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-06-30	$722,159	5,716	+4.4%	Shares	Sole	2026-07-30
2026-03-31	$763,050	5,475	+13.1%	Shares	Sole	2026-05-12
2025-12-31	$593,938	4,839	+2.8%	Shares	Sole	2026-02-04
2025-09-30	$522,477	4,707	+4.2%	Shares	Sole	2025-11-12
2025-06-30	$500,799	4,517	+12.7%	Shares	Sole	2025-08-14
2025-03-31	$449,208	4,009	+6.3%	Shares	Sole	2025-05-02
2024-12-31	$348,327	3,771	-29.3%	Shares	Sole	2025-01-30
2024-09-30	$447,286	5,335	+8.6%	Shares	Sole	2024-10-28
2024-06-30	$337,149	4,914	+12.9%	Shares	Sole	2024-07-25
2024-03-31	$318,784	4,352	-15.5%	Shares	Sole	2024-04-23
2023-12-31	$417,201	5,150	+5.3%	Shares	Sole	2024-02-07
2023-09-30	$366,381	4,889	+6.5%	Shares	Sole	2023-10-26
2023-06-30	$353,828	4,591	+13.8%	Shares	Sole	2023-08-02
2023-03-31	$334,700	4,034	+9.6%	Shares	Sole	2023-04-11
2022-12-31	$315,842	3,679	—	Shares	Sole	2023-01-19
No filing history on record for this holder in this stock.